Pharmacogenomics: Will the promise be fulfilled?

Nature Reviews Genetics

Volumn 12, Issue 1, 2011, Pages 69-73

  Altman, Russ B ^a   Kroemer, Heyo K ^b   McCarty, Catherine A ^c   Ratain, Mark J ^d   Roden, Dan ^e  

^a Stanford University   (United States)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c MARSHFIELD CLINIC   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2D6; LUMIRACOXIB; TAMOXIFEN; WARFARIN;

BIOINFORMATICS; BREAST CANCER; CLINICAL PRACTICE; DNA POLYMORPHISM; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE ACCESS; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

CLINICAL MEDICINE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 78650303722     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg2920     Document Type: Review

References (22)

1. Jones, S. J. M. et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 11, R82 (2010).
2. Ashley, E. A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
3. Roden, D. M. & Stein, C. M. Clopidogrel and the concept of high risk pharmacokinetics. Circulation 11 9, 2127-2130 (2009).
4. Roden, D. M., Wilke, R. A., Kroemer, H. K. & Stein, C. M. Pharmacogenomics - the genetics of variable drug responses. Circulation (in the press).
5. Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
6. Singer, J. B. et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature Genet. 42, 711-714 (2010).
7. Rieder, M. J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
8. Hulot, J. S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006).
9. Cooper, G. M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 11 2, 1022-1027 (2008).
10. Shuldiner, A. R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
11. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
12. Daly, A. K. et al. HLA?B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genet. 41, 816-819 (2009).
13. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
14. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
15. Pao, W. & Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Rev. Cancer 10, 760-774 (2010).
16. Klein T. E. et al. Estimation of warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
17. Goldstein, D. B. & Hirschhorn, J. N. In genetic control of disease, does "race" matter? Nature Genet. 36, 1243-1244 (2004).
18. Hanratty, B., Zhang, T. & Whitehead, M. How close have universal health systems come to achieving equity in use of curative services? A systematic review. Int. J. Health Serv. 37, 89-109 (2007).
19. Kroemer, H. K. & Meyer zu Schwabedissen, H. E. A piece in the puzzle of personalized medicine. Clin. Pharmacol. Ther. 87, 19-20 (2010).
20. McCarty, C. A. & Wilke, R. A. Biobanking and pharmacogenomics. Pharmacogenomics 11, 637-642 (2010).
21. Roden, D. M. & Brown, N. J. Preprescription genotyping: not yet ready for prime time, but getting there. Circulation 103, 1608-1610 (2001).
22. Collins, F. Opportunities and challenges for the NIH-an interview with Francis Collins. Interview by Robert Steinbrook. N. Engl. J. Med. 361, 1321-1323 (2009).